Dimensional Fund Advisors LP Decreases Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Dimensional Fund Advisors LP reduced its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 14.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,329,065 shares of the biopharmaceutical company's stock after selling 233,118 shares during the period. Dimensional Fund Advisors LP owned about 2.33% of Agios Pharmaceuticals worth $43,674,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Venturi Wealth Management LLC purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $33,000. Wingate Wealth Advisors Inc. purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $53,000. Sterling Capital Management LLC grew its stake in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after acquiring an additional 1,587 shares during the period. KBC Group NV increased its holdings in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares during the last quarter. Finally, AlphaQuest LLC raised its stake in Agios Pharmaceuticals by 106.2% in the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after acquiring an additional 2,338 shares during the period.

Agios Pharmaceuticals Trading Down 5.4 %

Shares of Agios Pharmaceuticals stock traded down $1.63 during trading on Tuesday, hitting $28.34. The stock had a trading volume of 836,971 shares, compared to its average volume of 700,115. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 2.50 and a beta of 0.77. The business's 50-day moving average is $29.60 and its 200 day moving average is $37.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Buying and Selling

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares in the company, valued at $3,864,798. The trade was a 4.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.93% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. Scotiabank cut their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday. Finally, StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 1st. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $56.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.